UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Sabra Health Care REIT - Sabra Health Care REIT (NASDAQ:SBRA)

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Sabra Health Care REIT (NASDAQ: SBRA), and slightly raised its price target from $23.00 to $24.00.Jefferies noted, “SBRA continues to successfully reduce exposure to both SUNH and the SNF sector through accretive acquisitions. We still see upside via: 1) multiple expansion through further portfolio diversification, and 2) earnings accretion from acquisitions. Raising PT to $24 and maintaining Buy rating.”Sabra Health Care REIT closed on Tuesday at $21.50.

20-Year Pro Trader Reveals His "MoneyLine"

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!